ADIPOQ and Hyperglycemia: (2017) in high‐fat fed and streptozotocin‐induced diabetic mice found that different concentrations of intravenous‐delivered adiponectin (10, 25, and 100 mg/kg) protected the animals against hyperglycemia, which may be one of the reason why END was also able to partially protect the animals against hyperinsulinemia.